February 2006

[CURRICULUM VITAE]{.underline}

[Name]{.underline}: Thomas J. Sayers

[Date and Place of Birth]{.underline}: November 7, 1952; Rotherham,
South Yorkshire, England

[Citizenship]{.underline}: British

[Marital Status]{.underline}: Married; 2 children

[Education]{.underline}:

1970-1973 B.S. (Biochemistry), Queen Elizabeth College

University of London, London, England

1973-1976 Ph.D. (Biochemistry), Chelsea College

University of London, London, England

[Brief Chronology of Employment]{.underline}:

1977 Research Assistant, Open University, BBC TV

1977-1980 Post-Doctoral position, Medical Clinic

University of Tubingen, West Germany

1980-1983 Post-Doctoral position, Sandoz Research Institute, Vienna,
Austria

1983-1984 Lab-Leader, Sandoz Research Institute, Vienna, Austria

> 1984-1985 Guest Researcher, BRMP, DCT, NCI,
>
> Biological Therapeutics Branch, Frederick, MD
>
> 1985-1986 Lab-Leader, Sandoz Research Institute, Vienna Austria
>
> 1986-Present Principal Investigator, Basic Research Program, SAIC,
>
> NCI-Frederick, Frederick, MD

[Societies]{.underline}:

American Association of Cancer Research

American Association of Immunologists

Society for Leukocyte Biology

[Editorial Boards:]{.underline}

1998. Associate Editor, Journal of the National Cancer Institute

      [Journal Reviews:]{.underline}

> Reviewer -- Science, Journal of Experimental Medicine, Nature, Nature
> Medicine, Nature Immunology, Journal of Leukocyte Biology, Journal of
> International Cancer Research, Journal of Immunology, Journal of
> Biological Chemistry, Journal of Clinical Immunology, Journal of Cell
> Science, International Journal of Immunopharmacology, International
> Journal of Cancer, European Journal of Cancer, Cytokine, Clinical
> Cancer
>
> Research, Cellular Immunology, Blood, and Journal of National Cancer
> Institute

[Other Contributions:]{.underline}

*[Thesis Advisor:]{.underline}*

> Karen Abdool, Ph.D. "Tumor recognition by CTL and NK cells: Importance
> of Activating (LFA-1, NKG2D) Receptors. Ligands (ICAM-1) and Cytokines
> (IL-18, IL-2) on Tumor Destruction" Howard University Medical School,
> Dept of Microbiology (July 2004)

*[External Thesis Examiner:]{.underline}*

Jamie Ziebold, M.Sc., Hood College, Frederick, MD (November 1999)

Joanne Davis, Ph.D., University of Melbourne, Australia (September 2001)

Marguerite Buzza, Ph.D., Monash University, Victoria, Australia (April
2004)

Erika Cretney Ph.D, University of Melbourne, Australia (December 2004)

Jinrong Cheng, University of Buffalo, Buffalo, NY (June 2005)

William Hallett, Ph.D., University of Nevada, Reno, NV (ongoing)

*[Current MTA's and CRADAs:]{.underline}*

#01306 CRADA Millennium Pharmaceuticals

#14639-03 MTA Washington University, St. Louis, MI

#01880 CRADA Genentech and Amgen

#17107-04 MTA Genentech

[Committees and Boards:]{.underline}

Organizing Committees for SAIC Retreat (2002-2004)

Animal Users Committee (Bldg 567), Frederick, MD (2001-Present)

[Research Interests]{.underline}:

> Immunotherapy of cancer, role of activated lymphocytes or cytokines;
> Mechanism of cell-mediated killing of tumor cells and identification
> of relevant molecules; Identification of apoptotic (cell death)
> pathways in tumor cells in response to immunotherapy; Biological
> role(s) of granule serine proteases (granzymes).

[Patents:]{.underline}

US Patent #5,500,344 issued March 19, 1996.

"Serine Protease and Uses Thereof"

[Selected Invited Presentations (last 5 years):]{.underline}

> Speaker Department of Pathology, Oxford University, UK (February 2000)
>
> Speaker Royal Free Hospital School of Medicine, UK (February 2000)
>
> Speaker Nottingham Trent University, Nottingham, UK (February 2000)
>
> Speaker EUCAPS Meeting London, UK (February 2000)
>
> Speaker Cytokine Interest Group Symposia: TNF superfamily of ligands
> and receptors. Frederick, MD (September 2000)
>
> Speaker Progress in Vaccination Against Cancer (PIVAC)
>
> Cambridge University, UK (July 2001)
>
> Speaker Millennium Pharmaceuticals, Cambridge, MA (August 2001)
>
> Speaker Society for Biological Therapy, Washington, DC (November 2001)
>
> Speaker Sheffield Hallam University, Sheffield, UK (February 2002)

Speaker FASEB, New Orleans, LA (April 2002)

> Speaker Apoptosis and Immunity, 2002 FASEB Research Conference
>
> Tucson, AZ (July 2002)

Speaker TNF Superfamily Conference, San Diego, CA (November 2002)

Speaker University of Nevada, Reno, NV (November 2002)

> Speaker Frederick Faculty Seminar Series, Frederick, MD (March 2003)

Speaker University of Nevada, Reno, NV (March 2003)

Speaker Immunology Faculty Seminar, NCI Bethesda, Bethesda, MD (May
2003)

> Speaker Osaka University, Osaka, Japan (October 2003)
>
> Speaker Juntendo University, Tokyo, Japan (October 2003)
>
> Speaker Nagoya University, Nagoya, Japan (October 2003)
>
> Speaker Kurume University Medical School, Kurume, Japan (October 2003)
>
> Speaker International Society of Biological Therapy, Washington, DC
>
> (November 2003)
>
> Speaker Human Genome Sciences Inc., Rockville, MD (November 2003)
>
> Speaker Molecular Targets Faculty Seminar, NCI Frederick, MD (December
> 2003)
>
> Speaker Pediatric Oncology Branch, NCI Bethesda, Bethesda, MD (April
> 2004)
>
> Speaker Regional Cancer Center Consortium for the Biological Therapy
> of Cancer (7th annual meeting), Roswell Park Cancer Institute,
> Buffalo, NY (February 2004)
>
> Speaker Roswell Park Cancer Institute, Buffalo, NY (February 2004)
>
> Speaker- University of Reno, Nevada (March 2004)
>
> Project Molecular Targets Development Program, NCI Frederick, MD
>
> Proposal (April 2004)
>
> Speaker- Progress in Vaccination against Cancer (PIVAC), Freudenstadt,
> Black Forest, Germany (September 2004)
>
> Speaker- Kings College, Department of Medicine, University of London
>
> (March 2005)
>
> Speaker- Royal Free Hospital, Anthony Nolan Institute (March 2005)

Speaker- Nottingham Trent University (March 2005)

Speaker- Apoptosis and Immunity Meeting, Palm Cove, Australia (June
2005)

Speaker- Peter MacCallum Cancer Institute, Melbourne, Australia (June
2005)

[Present Address]{.underline}: 19108 Manor Church Road

Boonsboro, MD 21713

[BIBLIOGRAPHY]{.underline}

1\. Sayers, T.J., Binder, T., and Berg, P.A.: Heterogeneity of
antimitochondrial antibodies characterization and separation of the
antigen associated with pseudolupes erythematosus syndrome. [Clin. Exp.
Immunol]{.underline}. 37: 68-75, 1979.

2\. Berg, P.A., Wiedmann, K.H., Sayers, T.J., Kloppel, G., and Linder,
H.: Serological classification of chronic cholestatic liver disease by
the use of two different types of antimitochondrial antibody.
[Lancet]{.underline} 2: 1329-1332, 1980.

3\. Sayers, T.J., Leoutsakos, A., Berg, P.A., and Baum, H.:
Antimitochondrial antibodies (AMA) in primary biliary cirrhosis:
Separation of the complement fixing antigen from the mitochondrial
F1-ATPase. [J. Bioenerg. Biomemb]{.underline}. 13: 225-267, 1981.

4\. Lindenborn-Fotinos, J., Sayers, T.J., and Berg, P.A.: Mitochondrial
antibodies in primary biliary cirrhosis. VI. Association of the
complement fixing antigen with a component of the mitochondrial
F1-ATPase complex. [Clin. Exp. Immunol]{.underline}. 50: 267-274, 1982.

5\. Sayers, T., Rossiter, H., Chung, T., Hren, A., and Armerding, D.: In
vivo activation of murine natural killer cells function by human
recombinant DNA interleukin-2. [Immunobiology]{.underline} 169: 303-318,
1985.

6\. Sayers, T.J., Ransom, J.H., Denn III, A.C., Shepard, H.M.,
Herberman, R.B., and Ortaldo, J.R.: Cytostatic factors produced by
lymphocytes in response to tumor cells. In: [Leukocytes and Host
Defense]{.underline}, Oppenheim, J.J. and Jacobs, D. (Eds), Alan R.
Liss, Inc., New York, NY, 1986, pp. 441-446.

7\. Sayers, T.J., Mason, A.T., and Ortaldo, J.R.: Regulation of human
natural killer cell activity by interferon-γ: Lack of a role in
interleukin 2-mediated augmentation. [J. Immunol]{.underline}. 136:
2176-2180, 1986.

8\. Sayers, T.J., Ransom, J.R., Denn III, A.C., Herberman, R.B., and
Ortaldo, J.R.: Analysis of a cytostatic lymphokine produced by
incubation of lymphocytes with tumor cells: Relationship to leukoregulin
and distinction from recombinant lymphotoxin, recombinant tumor necrosis
factor, and natural killer cytotoxic factor. [J. Immunol]{.underline}.
137: 385-390, 1986.

9\. Ortaldo, J.R., Ransom, J.R., Sayers, T.J., and Herberman, R.B.:
Analysis of cytostatic/cytotoxic lymphokines: Relationship of natural
killer cytotoxic factor to recombinant tumor necrosis factor and
leukoregulin. [J. Immunol]{.underline}. 137: 2857-2863, 1986.

10\. Sayers, T.J., Macher, I., Chung, J., and Kugler, E.: The production
of tumor necrosis factor by mouse bone marrow-derived macrophages in
response to bacterial lipopolysaccharide and a chemically synthesized
monosaccharide precursor. [J. Immunol]{.underline}. 138: 2935-2940,
1987.

11\. Sayers, T.J., Wiltrout, T.A., Bull, C.A., Denn, A.C., Pilaro, A.M.,
and Lokesh, B.: Effect of cytokines on polymorphonuclear neutrophil
infiltration in the mouse: prostaglandin- and leukotriene-independent
induction of infiltration by IL-1 and tumor necrosis factor. [J.
Immunol]{.underline}. 141: 1670-1677, 1988.

12\. Haslberger, A., Sayers, T., Reiter, H., Chung, J., and Schutze, E.:
Reduced release of TNF and PCA from macrophages of tolerant mice.
[Circulatory Shock]{.underline} 26: 185-192, 1988.

13\. Pilaro, A.M. and Sayers, T.J.: Chemotaxis of rat peripheral blood
large granular lymphocytes (LGL) to activators of protein kinase C. In:
[Natural Killer Cells]{.underline}, Ades, E.W. and Lopez, C. (Eds),
Basel, Karger, 1989, pp. 84-87.

14\. Sayers, T J. and Wiltrout, T.A.: Differing Roles for Interleukin 2
and Interferonγ in the Augmentation of Mouse Peritoneal Natural Killer
Cell Activity In Vivo. In: [Natural Killer Cells,]{.underline} Ades,
E.W. and Lopez, C. (Eds), Basel, Karger, 1989, pp. 88-91.

15\. Sayers, T.J. and Wiltrout, R.H.: Regulation and Functions of
Natural Killer (NK) Cells. In: [Immunopharmacology,]{.underline} Rogers,
T.J. and Gilman, S. (Eds), The Caldwell, Telford Press, 1989, pp.
343-379.

16\. Pilaro, A.M., Sayers, T.J., Reynolds, C.W., Ortaldo, J.R., and
Wiltrout, R.H.: Chemotaxis of rat large granular lymphocytes involves
activation of protein kinase C. In: [Progress in Leukocyte Biology,
Cellular Basis of Immune Modulation,]{.underline} Kaplan, J.G. (Ed),
Alan R. Liss, New York, NY, Vol 9, 1988, pp. 337-340.

17\. Pawelec, G., Sayers, T.J., and Busch, F.W.: Selective inhibition of
interleukin 2 but not interferon-γ, tumor necrosis factor-α or
granulocyte/macrophage colony stimulating factor secretion by human
helper T cell clones after antigen-driven tolerisation. [Immunol.
Lett]{.underline}. 20: 187-192, 1989.

18\. Pawelec, G., Sayers, T., and Busch, F.W.: Regulation of normal
myelopoiesis and chronic myelogenous leukaemia cell proliferation
through a non-cytotoxic mechanism by a γ/δ T cell clone. [Immunol.
Lett]{.underline}. 22: 199-204, 1989.

19\. Lokesh, B.R., Sayers, T.J., and Kinsella, J.E.: Interleukin-1 and
tumor necrosis factor synthesis by mouse peritoneal macrophages is
enhanced by dietary n-3 polyunsaturated fatty acids. [Immunol.
Lett]{.underline}. 23: 281-286, 1990.

20\. Sayers, T.J., Mason, L.H., and Wiltrout, T.A.: Trafficking and
activation of murine natural killer cells: Differing roles for IFN-γ and
IL-2. [Cell. Immunol]{.underline}. 127: 311-326, 1990.

21\. Sayers, T.J., Wiltrout, T.A., McCormick, K., Husted, C., and
Wiltrout, R.H.: Antitumor effects of IFN-α and IFN-γ on a murine renal
cancer (Renca) in vitro and in vivo. [Cancer Res]{.underline}. 50:
5414-5420, 1990.

22\. Pilaro, A.M., Sayers, T.J., and Wiltrout, R.H.: Potential mechanism
for the recruitment of large granular lymphocytes following treatment
with biological response modifiers. In: [The Physiological and
Pathological Effects of Cytokines,]{.underline} Powanda, M.C.,
Oppenheim, J.J., Kluger, M.C., Dinarello, C.A. (Eds), Wiley-Liss, Inc.,
Boston, MA, 1990, pp. 381-386.

23\. Wiltrout, R.H., Hornung, R.L., Futami, H., Young, H.A., and Sayers,
T.J.: Involvement of cytokines in combined modality preclinical
approaches to cancer treatment. In: [The Biology and Clinical
Application of Interleukin-2,]{.underline} Rees, R.C. (Ed), IRL Press,
Oxford, 1990, pp. 90-97.

24\. Pilaro, A.M., Sayers, T.J., McCormick, K.L., Reynolds, C.W., and
Wiltrout, R.H.: An improved in vitro assay to quantitate chemotaxis of
rat peripheral blood large granular lymphocytes (LGL). [J. Immunol.
Methods]{.underline} 135: 213-223, 1990.

25\. Reynolds, C.W. and Sayers, T.J.: Identification and functional
characteristics of lymphocytes with natural killer activity. In:
[Monograph on the Pathology of Laboratory Animals, Hemopoietic
System,]{.underline} Jones, T.C., Ward, J.M., Moore, U., and Hunt, R.D.
(Eds) Springer-Verlag, New York, NY, 1990, pp. 103-110.

26\. Wiltrout, R.H., Hornung, R.L., Futami, H., Back, T.T., Young, H.
A., and Sayers, T.J.: Murine renal cancer (Renca) model: Background and
preclinical studies. In: [Immuno-therapy of Renal Cell
Carcinoma]{.underline}, Debruyne, F.M.J., Bukowski, R.M., Pontes, J.E.,
and de Mulder, P.H.M. (Eds), Springer-Verlag, Heidelberg, 1991, pp.
13-19.

27\. Neta, R., Sayers, T.J., and Oppenheim, J.J.: Relationship of TNF to
interleukins. [Immunol. Ser]{.underline}. 56: 499-566, 1992.

28\. Sayers, T.J., Wiltrout, T.A., Sowder, R., Munger, W.L., Smyth,
M.J., and Henderson, L. E.: Purification of a factor from the granules
of a rat natural killer cell line (RNK) that reduces tumor cell growth
and changes tumor morphology: Molecular identity with granule serine
protease (RNKP-1). [J. Immunol]{.underline}. 148: 292-300, 1992.

29\. Neta, R., Sayers, T., and Oppenheim, J.J.: Relationship of tumor
necrosis factor to interleukins. In: [Tumor Necrosis Factor: Structure,
Function, and Mechanisms of Injury]{.underline}, Osawa, T. and Bonavida,
B. (Eds), Marcel Dekker, New York, NY, 1992, pp. 499-567.

30\. Smyth, M.J., Wiltrout, T., Trapani, J.A., Ottaway, K.S., Sowder,
R., Henderson, L.E., Kam, C-M., Powers, J.C., Young, H.A., and Sayers,
T.J.: Purification and cloning of a novel serine protease, RNK-Met-1,
from the granules of a rat natural killer cell leukemia. [J. Biol.
Chem]{.underline}. 267: 22418-24425, 1992.

31\. Forough, R., Zhan, X., MacPhee, M., Friedman, S., Engleka, K.A.,
Sayers, T., Wiltrout, R.H., and Maciag, T.: Differential transforming
abilities of non-secreted and secreted forms of human fibroblast growth
factor-1. [J. Biol. Chem]{.underline}. 268: 2960-2968, 1993.

32\. Murphy, W.J., Conlon, K.C., Sayers, T.J., Wiltrout, R.H., Back,
T.C., Ortaldo, J.R., and Longo, D.L.: Engraftment and activity of
anti-CD3-activated human peripheral blood lymphocytes transferred into
mice with severe combined immune deficiency. [J. Immunol]{.underline}.
150: 3634-3642, 1993.

33\. Sayers, T.J., Mason, L.H., Pilaro, A.M., Wiltrout, T.A.,
Komschlies, K., Munger, W.L., and Wiltrout, R.H.: Substrate-specific
proteases (BLT-esterase) are localized predominantly in the natural
killer cells of unprimed mice. [J. Leukoc. Biol]{.underline}. 53:
454-461, 1993.

34\. Smyth, M.J., Sayers, T.J., Wiltrout, T., and Trapani, J.A.:
Met-ase: cloning and distinct chromosomal location of a novel granzyme
preferentially expressed in human natural killer cells. [J.
Immunol]{.underline}. 151: 6195-6205, 1993.

35\. Murphy, W.J., Back, T.C., Conlon, K.C., Komschlies, K.L., Ortaldo,
J.R., Sayers, T.J., Wiltrout, R.H., and Longo, D.L.: Antitumor effects
of interleukin-7 and adoptive immunotherapy on human colon carcinoma
development in vivo. [J. Clin. Invest]{.underline}. 92: 1918-1924, 1993.

36\. Kaneda, K., Pilaro, A.M., Sayers, T.J., Nagashima, K., Gonda, M.A.,
Ortaldo, J.R., and Wiltrout, R.H.: Quantitative analysis of rod-cored
vesicles and dense granules of large granular lymphocytes in the liver,
spleen and peripheral blood of rats. [Cell Tissue Res]{.underline}. 276:
187-195, 1994.

37\. Sayers, T.J., Wiltrout, T.A., Smyth, M.J., Ottaway, K.S., Pilaro,
A.M., Sowder, R., Henderson, L.E., Sprenger, H., and Lloyd, A.R.:
Purification and cloning of a novel serine protease, RNK-tryp 2, from
the granules of a rat natural killer cell leukemia. [J.
Immunol]{.underline}. 152: 2289-2297, 1994.

38\. Pilaro, A.M., Taub, D.D., McCormick, K.L., Williams, H.M., Sayers,
T.J., Fogler, W.E., and Wiltrout, R.H.: TNF-α is a principal cytokine
involved in the recruitment of NK cells to liver parenchyma. [J.
Immunol]{.underline}. 153: 333-342, 1994.

39\. Baker, E., Sutherland, G.R., Sayers, T.J., and Smith, M.J.: The
genes encoding human NK granule serine proteases, human tryptase-2
(TRYP2) and human granzyme A (HFSP), both map to chromosome 5Q11-q12 and
define a new locus for cytotoxic lymphocyte granule tryptases.
[Immunogenetics]{.underline} 40: 235-237, 1994.

40\. MacPhee, M.J., Wiltrout, R.H., McCormick, K.L., Sayers, T.J., and
Pilaro, A.M.: A method for obtaining and culturing large numbers of
purified organ-derived murine endothelial cells. [J. Leukoc.
Biol]{.underline}. 55: 467-475, 1994.

41\. Giardina, S.L., Anderson, S.K., Sayers, T.J., Chambers, W.H.,
Palumbo, G.A., Young, H.A., and Ortaldo, J.R.: Selective loss of NK
cytotoxicity in antisense NK-TR1 rat LGL cell lines: abrogation of
antibody independent tumor and virus-infected target cell killing. [J.
Immunol]{.underline}. 154: 80-87, 1995.

42\. Ortaldo, J.R., Wiltrout, T.A., Sayers, T.J., Yagita, H., and
Winkler-Pickett, R.T.: Characterization of a non-granule associated
pore-forming protein in agranular lymphocytes. [J. Leukoc.
Biol]{.underline}. 57: 897-903, 1995.

43\. Smyth, M.J., Hulett, M.D., Thia, K.Y.T., Young, H.A., Sayers, T.J.,
Carter, C.R.D., and Trapani, J.A.: Cloning and characterization of a
novel NK-cell specific serine protease gene and its functional
5\'-flanking sequences. [Immunogenetics]{.underline} 42: 101-111, 1995.

44\. Franco, J.L., Ghosh, P., Wiltrout, R.H., Carter, C.R.D., Zea, A.H.,
Momozaki, N., Ochoa, A.C., Longo, D.L., Sayer, T.J., and Komschlies,
K.L.: Partial degradation of T-cell signal transduction molecules by
contaminating granulocytes during protein extraction of splenic T cells
from tumor-bearing mice. [Cancer Res]{.underline}. 55: 3840-3846, 1995.

45\. Taub, D.D., Sayers, T.J., Carter, C.R.D., and Ortaldo, J.R.: Alpha
and beta chemokines induce NK cell migration and enhance NK-mediated
cytolysis. [J. Immunol]{.underline}. 155: 3877-3888, 1995.

46\. Kaneda, K., Sayers, T.J., Wiltrout, T.A., Pilaro, A.M., Kojima, A.,
Nagashima, K., Gonda, M.A., Ward, J.M., Reynolds, C.W., Ortaldo, J.R.,
and Wiltrout, R.H.: Rod-cored vesicles in large granular lymphocyte
(LGL) leukemia cells of rats: Alterations induced following metastasis
to the liver. [Biomed. Res.]{.underline} 17: 53-65, 1996.

47\. Sayers, T.J., Lloyd, A.R., McVicar, D.W., O\'Connor, M.D., Kelly,
J.M., Carter, C.R.D., Wiltrout, T.A., Wiltrout, R.H., and Smyth, M.J.:
Cloning and Expression of a second human NK cell granule tryptase,
HNK-Tryp-2/granzyme 3. [J. Leukoc. Biol]{.underline}. 59: 763-768, 1996.

48\. Carter, C.R.D., Sayers, T.J., Wiltrout, R.H., Turcovski-Corrales,
S.M., and Taub, D.D.: Generation of antigenic peptides by lymphocyte
granule serine proteases (granzymes). [Cell. Immunol.]{.underline} 172:
235-245, 1996.

49\. Chertov, O., Ueda, H., Xu, L.L., Tani, K., Murphy, W.J., Wang,
J.M., Howard, Z., Sayers, T.J., and Oppenheim, J.J.: Identification of
human neutrophil derived cathepsin G and azurocidin/cap37 as
chemoattractants for mononuclear cells and neutrophils. [J. Exp.
Med.]{.underline} 186: 739-747, 1997.

50\. Kim, K., Lee, C-K., Sayers, T.J., Muegge, K., and Durum, S.K.: The
trophic action of IL-7 on pro-T cells: Inhibition of apoptosis of
pro-T1, -T2, and -T3 cells correlates with Bcl-2 and bax levels and is
independent of Fas and p53 pathways. [J. Immunol.]{.underline} 160:
5735-5741, 1998.

51\. Sayers, T.J., Brooks, A.D., Lee, J-K., Fenton, R.G., Komschlies,
K.L., Wigginton, J.M., Winkler-Pickett, R., and Wiltrout, R.H.:
Molecular mechanisms of immune-mediated lysis of murine renal cancer:
differential contributions of perforin-dependent versus Fas-mediated
pathways in lysis by NK and T cells. [J. Immunol]{.underline}. 161:
3957-3965, 1998.

52\. Fenton, R.G., Hixon, J.A., Wright, P.W., Brooks, A.D., and Sayers,
T.J.: Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by
oncogenic Ras. [Cancer Res.]{.underline} 58: 3391-3400, 1998.

53\. Lee, J-K., Sayers, T.J., Brooks, A.D., Back, T.C., Young, H.A.,
Komschlies, K.L., Wigginton, J.M., and Wiltrout, R.H.: IFN-γ-dependent
delay of in vivo tumor progression by Fas over expression on murine
renal cancer cells. [J. Immunol.]{.underline} 164: 231-239, 2000.

54. Sayers, T.J., Brooks, A.D., Seki, N., Smyth, M.J., Yagita, H.,
    Blazar, B.R., and Malyguine, A.M.: T cell lysis of murine renal
    cancer: multiple signaling pathways for cell death via Fas. [J.
    Leukoc. Biol.]{.underline} 68: 81-86, 2000.

55. Sayers, T.J., Brooks, A.D., Ward, J.M., Hoshino, T., Bere, W.E.,
    Wiegand, G.W., Kelley, J.M., and Smyth, M.J.: The restricted
    expression of granzyme M (Gzm M, Met-ase) in human lymphocytes. [J.
    Immunol.]{.underline} 166: 765-771, 2001.

56. Smyth, M.J., Kelly, J.M., Sutton, V.R., Davis, J.E., Browne, K.A.,
    Sayers, T.J., and Trapani, J.A.: Unlocking the secrets of cytotoxic
    granule proteins. [J. Leukoc. Biol.]{.underline} 70: 18-29, 2001.

57. Derby, E. Reddy, V., Kopp, W., Nelson, E., Baseler, M., Sayers, T.,
    and Malyguine, A.: Three-color flow cytometric assay for the study
    of the mechanisms of cell-mediated cytotoxicity. [Immunol.
    Letters]{.underline} 78: 35-39, 2001.

58. Seki, N., Brooks, A.D., Back, T.C., Carter, C.R.D., Parsoneault,
    E.M., Wiltrout, R.H., and Sayers, T.J.: Tumor-specific CTL kill
    murine renal cancer cells using both perforin and Fas
    ligand-mediated lysis I nvitro, but cause tumor regression in vivo
    in the absence of perforin. [J. Immunol.]{.underline} 168:
    3484-3492, 2002.

59. Malyguine, A., Derby, E., Brooks, A. Reddy, V., Baseler, M., and
    Sayers, T.: Study of diverse mechanisms of cell-mediated
    cytotoxicity in gene-targeted mice using flow cytometric
    cytotoxicity assay. [Immunol. Letters]{.underline} 83: 55-59, 2002.

60. Seki, N., Hauakawa, Y., Brooks, A.D., Wine, J., Wiltrout, R.H.,
    Yagita, H., Tanner, J.E., Smyth, M.J., and Sayers, T.J.: Tumor
    necrosis factor-related apoptosis-inducing ligand-mediated apoptosis
    is an important endogenous mechanism for resistance to liver
    metastases in murine renal cancer. [Cancer Res.]{.underline} 63:
    207-213, 2003.

61. Murphy, W.J., Welniak, L., Back, T., Hixon, J., Subleski, J., Seki,
    N., Wigginton, J.M., Wilson, S.E., Blazar, B.R., Malyguine, A.M.,
    Sayers, T.J., and Wiltrout, R.H.: Synergistic anti-tumor responses
    after administration of agonistic antibodies to CD40 and IL2:
    Coordination of dendritic and CD8^+^ cell responses. [J.
    Immunol.]{.underline} 170: 2727-2733, 2003.

62. Lee, J-K., Sayers, T.J., Back, T.C., Brooks, A.D., Wigginton, J.M.,
    and Wiltrout, R.H.: Lack of FasL-mediated killing leads to in vivo
    tumor promotion in mouse Lewis lung cancer. [Apoptosis]{.underline}
    8: 151-160, 2003.

63. Sayers, T.J.: Granzyme M, a profile of innate immune lymphocytes?
    [Blood (Capsule Commentary)]{.underline} 101: 3342b-3343b, 2003.

64. Komatsu, M., Mammolenti, M., Jones, M., Jurecic, R., Sayers, T.J.,
    and Levy, R.B.: Antigen-primed CD8^+^ T cells can mediate resistance
    preventing allogeneic marrow engraftment in the simultaneous absence
    of perforin, CD95L, TNFR1 and TRAIL dependent killing.
    [Blood]{.underline} 101: 3991-3999, 2003.

65. Sayers, T.J., Brooks, A., Koh, C., Ma, W., Seki, N., Raziuddin, A.,
    Blazar, B., Zhang, Z., Elliott, P.J., and Murphy, W.J.: The
    proteasome inhibitor PS-341 sensitizes some neoplastic cells to
    TRAIL-mediated apoptosis. [Blood]{.underline} 102: 303-310, 2003.

66. Shafer-Weaver, K., Sayers, T., Stroble, S., Derby, E., Ulderich, T.,
    Baseler, M., and Malyguine, A.: The granzyme B ELISPOT assay: An
    alternative to the 51Cr-release assay for monitoring cell-mediated
    cytotoxicity. [J. Transl. Med.]{.underline} 1: 14, 2003.

67. Malyguine, A., Shafer-Weaver, K., Derby, E., Burkett, M., Sayers,
    T., and Baseler, M.: Granzyme B and IFN- release by effector cells
    in cell-mediated cytotoxicity. Int'l. Cytokine Society Annual
    Meeting - [Int'l. Proceedings]{.underline} 105-110, 2003.

68. Takeda, K., Yamaguchi, N., Akiba, H., Kojima, Y., Hayakawa, Y.,
    Tanner, J.E., Sayers, T.J., Seki, N., Okumura, K., Yagita, H., and
    Smyth, M.J.: Induction of tumor-specific T-cell immunity by anti-DR5
    antibody therapy. [J. Exp. Med.]{.underline} 199: 437-448, 2004.

69. Sedelies, K.A., Sayers, T.J., Edwards, K.M., Chen, W., Pellicci,
    D.G., Godfrey, D.I. and Trapani, J.A.: Discordant regulation of
    granzyme H and granzyme B expression in human lymphocytes. [J. Biol.
    Chem]{.underline}. 279: 26581-26587, 2004.

70. Number range CHAPTERSun, K., Welniak, L.A., Panoskaltsis-Mortari,
    A., O'Shaughnessy, J.O., Liu, H., Barao, I., Riordan, W., Sitcheran,
    R., Wysocki, C., Serody, J.S., Blazar, B.R., Sayers, T.J., and
    Murphy, W.J.: Inhibition of acute graft-versus-host disease with
    retention of graft-versus-tumor effects by the proteasome inhibitor
    bortezomib. [Proc. Natl. Cancer Inst.]{.underline} 101: 8120-8125,
    2004.

71. Sayers, T.J.: TNF-related apoptosis inducing ligand (TRAIL):
    Combination with proteasome inhibition for anticancer therapy. In:
    [Proteasome Inhibitors in Cancer Therapy]{.underline}, J. Adams
    (Ed), Totowa, NJ, Humana Press, pp. 181-191, 2004.

72. Sayers, T.: Velcade plus Apo2L/Trail promotes apoptosis of Ca cells
    in murine studies. Invited Release in [Oncol. News
    Intl.]{.underline} 13: 5, 2004.

73. Takeda, K., Yamaguchi, N., Akiba, H., Kojima, Y., Hayakawa, Y.,
    Tanner, J.E., Sayers, T.J., Seki, N., Okumura, K., Yagita, H., and
    Smyth, M.J.: Induction of tumor-specific T cell immunity by anti-DR5
    antibody therapy. [J. Exp. Med.]{.underline} 199: 437-448, 2004.

74. Number range CHAPTERSmyth, M.J., Swann, J., Kelly, J.M., Cretney,
    E., Yokoyama, W.M., Diefenbach, A., Sayers, T.J., and Hayakawa, Y.:
    NKG2D recognition and perforin effector function mediate effective
    cytokine immunotherapy of cancer. [J. Exp. Med.]{.underline} 200:
    1325-1335, 2004.

75. Number range CHAPTERShafer-Weaver, K.A., Sayers, T., Kuhns, D.B.,
    Strobl, S., Burkett, M.W., Baseler, M., and Malyguine, A.:
    Evaluating the cytotoxicity of innate immune effector cells using
    the GrB ELISPOT assay. [J. Transl. Med]{.underline}. 2: 31, 2004.

76. Number range CHAPTERBrooks, A.D., and Sayers, T.J.: Reduction of the
    anti-apoptotic protein cFLIP enhances the susceptibility of human
    renal cancer cells to TRAIL-apoptosis. [Cancer Immunol.
    Immunother.]{.underline} 54: 499-505, 2005.

77. Number range CHAPTERSun, K., Wilkins, D.E.C., Anver, M.R., Sayers,
    T.J., Panoskaltsis-Mortari, A., Blazar, B.R., Welniak, L.A., and
    Murphy, W.J.: Differential effects of proteasome inhibition by
    bortezomib on murine acute graft-versus-host disease (GVHD): delayed
    administration of bortezomib results in increased GVHD-dependent
    gastrointestinal toxicity. [Blood]{.underline} 106: 3293-3299, 2005.

78. Sayers, T.J.: Mcl-1 reduction, releasing a death brake? [Blood
    Capsule (Commentary)]{.underline}, 105: 3005, 2005.

79. Lee, J-K., Seki, N., Sayers, T.J., Gruys, E.M., Murphy, W.J., and
    Wiltrout, R.H.: Constitutive expression of functional CD40 on mouse
    renal cancer cells: Induction of Fas-mediated killing and cytokine
    production by CD40L. [Cell. Immun.]{.underline} 235: 145-152, 2005.

80. Brooks, A.D., Ramirez, T., Toh, U., Onksen, J., Elliott, Peter J.,
    Murphy, W.J., and Sayers, T.J.: The proteasome inhibitor bortezomib
    (Velcade) sensitizes some human tumor cells to APO2L/TRAIL-mediated
    apoptosis. [Ann. NY Acad. Sci.]{.underline} 1059: 160-167, 2005.

81. Sayers, T.J., and Murphy, W.J.: Combining proteasome inhibition with
    TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer
    therapy. [Cancer Immunol. Immunother]{.underline}. 55: 76-84, 2006.

82. Cretney, E., Shanker, A., Yagita, H., Smyth, M.J., Sayers, T.J.:
    TNF-related apoptosis-inducing ligand as a therapeutic in
    autoimmunity and cancer. [Immunol. Cell Biol.]{.underline} 84:
    87-98, 2006.

    [IN PRESS]{.underline}

1\. Khan, T., Stauffer, J.K., Williams, R., Hixon, J.A., Salcedo, R.,
Lincoln, E., Back, T.C., Lockett, S., Sayers, T.J., and Wigginton, J.M.:
Proteasome inhibition to maximize the apoptotic potential of cytokine
therapy for murine neuroblastoma tumors. [J. Immunol.
3/2006]{.underline}.

2\. Number range CHAPTERAbdool, K., Cretney, E., Brooks, A.D., Kelly,
J.M., Swann, J., Shanker, A., Bere Jr., E.W., Yokoyama, W.M., Ortaldo,
J.R., Smyth, M.J., and Sayers, T.J.: NK cells use NKG2D to recognize a
mouse renal cancer (Renca), yet require ICAM-1 expression Number range
CHAPTERon the tumor cells for optimal perforin-dependent effector
functions. [J. Immunol]{.underline}., in press.